Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Iovance Biotherapeutics Ownership Summary

Iovance Biotherapeutics is owned by 21.60% institutional investors, 0.45% insiders, and 77.95% retail investors. Vanguard group is the largest institutional shareholder, holding 9.08% of IOVA shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.83% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Iovance Biotherapeutics	21.60%	0.45%	77.95%
Sector	Healthcare Stocks	479.67%	11.03%	-390.70%
Industry	Biotech Stocks	295.80%	10.97%	-206.77%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Vanguard group	27.53M	9.08%	$203.75M
Mhr fund management	28.97M	8.66%	$49.82M
Blackrock	21.23M	7.97%	$170.23M
Blackrock funding, inc. /de	23.24M	6.95%	$39.97M
State street	12.63M	4.74%	$101.25M
Long focus capital management	11.82M	3.53%	$20.33M
Invenomic capital management lp	8.29M	2.48%	$14.27M
Geode capital management	5.87M	1.94%	$43.46M
Goldman sachs group	4.11M	1.36%	$30.41M
Principal financial group	3.65M	1.20%	$26.99M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mhr fund management	28.97M	5.53%	$49.82M
Cm management	300.00K	1.98%	$2.22M
Orion investment	2.34M	1.42%	$4.02M
Palo alto investors lp	3.43M	1.25%	$5.90M
Invenomic capital management lp	8.29M	0.81%	$14.27M
Long focus capital management	11.82M	0.77%	$20.33M
Parametrica management	195.88K	0.63%	$336.91K
Soleus capital management	3.26M	0.37%	$5.61M
Boxer capital	750.00K	0.32%	$6.01M
Artal group	1.01M	0.21%	$8.11M

Top Buyers

Holder	Shares	% Assets	Change
Mhr fund management	28.97M	5.53%	4.55M
Invenomic capital management lp	8.29M	0.81%	2.80M
Long focus capital management	11.82M	0.77%	2.57M
State street	12.63M	0.00%	2.22M
Ubs group	2.70M	0.00%	2.08M

Top Sellers

Holder	Shares	% Assets	Change
Perceptive advisors	-	-	-12.71M
Hood river capital management	-	-	-9.22M
Macquarie group	-	-	-4.79M
Soleus capital management	3.26M	0.37%	-4.52M
Artisan partners limited partnership	-	-	-4.41M

New Positions

Holder	Shares	% Assets	Change	Value
Artal group	1.01M	0.21%	1.01M	$8.11M
Voss capital	672.57K	0.08%	672.57K	$1.16M
Quinn opportunity partners	614.20K	0.09%	614.20K	$1.06M
Voleon capital management lp	509.67K	0.05%	509.67K	$876.63K
Polar asset management partners	433.90K	0.01%	433.90K	$746.31K

Sold Out

Holder	Change
Nbc securities	-4.00
Sjs investment consulting	-4.00
Global financial private client	-4.00
Capital performance advisors llp	-11.00
Bell investment advisors	-43.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2025	24	-92.48%	69,746,593	-71.12%	21	0.34%	12	-92.36%	4	-95.40%
Dec 31, 2024	193	-35.02%	100,034,590	-57.33%	32	0.55%	92	-39.07%	50	-37.50%
Sep 30, 2024	292	-5.19%	234,393,808	0.82%	77	1.01%	149	-17.22%	80	-2.44%
Jun 30, 2024	305	2.69%	232,471,450	7.59%	87	1.23%	177	9.94%	82	-6.82%
Mar 31, 2024	297	18.33%	216,063,214	4.25%	84	1.19%	161	13.38%	88	31.34%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	9.67M	2.83%	-792.50K
Vanguard US Total Market Shares ETF	8.71M	2.66%	762.45K
iShares Russell 2000 ETF	6.05M	1.77%	-115.08K
Hood River Small-Cap Growth Instl	5.10M	1.53%	-
Macquarie Small Cap Core I	4.08M	1.22%	56.67K
Vanguard Small Cap Index	3.65M	1.07%	-24.46K
SPDR® S&P Biotech ETF	3.54M	1.06%	87.50K
Invenomic Institutional	3.28M	0.98%	3.28M
Delaware Small Cap Core I	2.61M	0.86%	1.84M
Fidelity Small Cap Index	2.78M	0.83%	-15.07K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 05, 2025	Kirby Daniel Gordon	Chief Commercial Officer	Buy	$55.20K
May 23, 2025	Puri Raj K.	Chief Regulatory Officer	Buy	$9.74K
May 14, 2025	Vogt Frederick G	Interim CEO & General Counsel	Buy	$42.25K
Nov 12, 2024	Maynard Ryan D	-	Sell	$503.00K
Feb 20, 2024	MCPEAK MERRILL A	-	Buy	$2.29M

Insider Transactions Trends

Date	Buy	Sell
2025 Q3	-	-
2025 Q2	3	-
2025 Q1	-	-
2024 Q4	-	1
2024 Q3	-	-

IOVA Ownership FAQ

Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 21.60%, followed by 0.45% insiders and 77.95% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 295.80%, which Iovance Biotherapeutics falls below.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Vanguard group (27.53M shares, 9.08%), Mhr fund management (28.97M shares, 8.66%), and Blackrock (21.23M shares, 7.97%). Together, they hold 25.71% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Mhr fund management is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 5.53% of its assets in 28.97M Iovance Biotherapeutics shares, valued at 49.82M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Iovance Biotherapeutics shares, with 2.83% of its total shares outstanding invested in 9.67M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools